Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23451044 | 1.00 | FOLH1 (0.51) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL3727817 | 0.87 | FOLH1 (0.53) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL1413149 | 0.87 | FOLH1 (0.53) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL209237 | 0.87 | FOLH1 (0.53) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL29741342 | 0.85 | FOLH1 (0.51) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL1116199 | 0.85 | FOLH1 (0.51) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL4951252 | 0.85 | GSR (0.52) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL787393 | 0.85 | FOLH1 (0.51) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL19737303 | 0.84 | RNPEP (0.53) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL1443500 | 0.82 | FOLH1 (0.56) | FOLH1GSRRNPEPSLC6A5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114938659-B | Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof | 中国医学科学院阜外医院 | 2025-03-04 | — | — | CN | claimed |
| CN-114938659-A | Cardiovascular disease onset risk assessment marker based on metabonomics data and application | 中国医学科学院阜外医院 | 2022-08-23 | — | — | CN | claimed |
| WO-2022166935-A1 | CARDIOVASCULAR DISEASE INCIDENCE RISK ASSESSMENT MARKER BASED ON METABOLOMIC DATA AND APPLICATION THEREOF | 中国医学科学院阜外医院 | 2022-08-11 | — | — | WO | claimed |
| CN-112509695-A | Acute coronary syndrome early warning method and device for stable coronary heart disease patient | 中国医学科学院阜外医院 | 2021-03-16 | — | — | CN | claimed |
| CN-112509704-A | Acute coronary syndrome early warning method and device based on metabonomics data | 中国医学科学院阜外医院 | 2021-03-16 | — | — | CN | claimed |
| US-12636372-B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| CN-114938659-B | Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof | 中国医学科学院阜外医院 | 2025-03-04 | — | — | CN | disclosed |
| US-20240277854-A1 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY TO THE LUNG | UNIV LELAND STANFORD JUNIOR (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118079011-A | Lytic cell penetrating complexes for delivery of nucleic acids to the lung | 利兰斯坦福初级大学董事会 | 2024-05-28 | — | — | CN | disclosed |
| US-11931416-B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| CN-113811334-B | Lytic cell penetrating complexes for delivery of nucleic acids to the lung | 利兰斯坦福初级大学董事会 | 2024-02-20 | — | — | CN | disclosed |
| CN-114938659-A | Cardiovascular disease onset risk assessment marker based on metabonomics data and application | 中国医学科学院阜外医院 | 2022-08-23 | — | — | CN | disclosed |
| CN-112509704-A | Acute coronary syndrome early warning method and device based on metabonomics data | 中国医学科学院阜外医院 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020160511-A1 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY TO THE LUNG | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-08-06 | — | — | WO | disclosed |
| US-7169892-B2 | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems | ASTELLAS PHARMA INC. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1591450-A1 | CONJUGATE FOR RETENTION IN BLOOD AND CANCER TISSUE-SPECIFIC DRUG DELIVERY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20050054026-A1 | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| US-5334379-A | Immunogenic; a bacterial capsular polymer bound to interferon or an interleukin | AMERICAN CYANAMID COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0482068-A1 | CYTOKINE AND HORMONE CARRIERS FOR CONJUGATE VACCINES | AMERICAN CYANAMID COMPANY (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991001146-A1 | CYTOKINE AND HORMONE CARRIERS FOR CONJUGATE VACCINES | PRAXIS BIOLOGICS, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931416-B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | ANXA3, ANXA11, IPO9 | FOLH1 765/4885GSR 2308/4885RNPEP 501/4885 |
| US-20240277854-A1 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY TO THE LUNG | RNASE1, IPO9, DNASE1L3 | FOLH1 428/4885GSR 2439/4885RNPEP 470/4885 |
| US-12636372-B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | NPC1L1, NPC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FOLH1 1100/4885GSR 1741/4885RNPEP 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.